ArticleBMC endocrine disorders2026
Elevated gamma glutamyl transferase levels as screening marker of stage 3-4 hepatic fibrosis in youth-onset type 2 diabetes mellitus: a retrospective chart review.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a comorbidity of type 2 diabetes mellitus (T2D) that can lead to metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis. With rising incidence of youth-onset T2D (YOT2D), there is a need for noninvasive screening tools for MASH with fibrosis. Although multiple screening guidelines recommend measuring alanine transaminase (ALT) at YOT2D diagnosis and at regular intervals, ALT has low sensitivity in identifying MASH with fibrosis. The objective of this study is to identify other noninvasive biomarkers in assessing liver fibrosis severity in YOT2D with MASLD.
methodsA single-center retrospective chart review was conducted on 51 patients with elevated liver transaminases, liver biopsy from 2010 to 2023, and diagnosis of T2D. Clinical, histopathological, imaging, and biochemical data were extracted from electronic medical records. Hepatic fibrosis prediction scores were calculated. Associations between these factors and stages of fibrosis were examined.
results59% of patients had no or stage 1–2 fibrosis and 41% had stage 3–4 fibrosis. Compared to those with no or stage 1–2 fibrosis, patients with stage 3–4 fibrosis were more likely to be male (p = 0.021), had a higher median gamma glutamyl transferase (GGT) (p = 0.026), and higher median liver stiffness on MRE (p = 0.011). For every 10 U/L increase in GGT, the odds of having stage 3–4 fibrosis increased by 20% (odds ratio: 1.20, 95% confidence interval: 1.05, 1.38; p = 0.007), adjusting for age, sex, hemoglobin A1C, and BMI z-score.
conclusionsUsing biopsy proven outcomes, we identified a positive association between GGT levels and hepatic fibrosis stages in YOT2D. Pediatric endocrinologists and primary care providers may consider incorporating GGT levels into the screening for MASLD in YOT2D patients with elevated liver enzymes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.